U.S. markets closed

Eledon Pharmaceuticals, Inc. (ELDN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.49+0.08 (+1.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close6.41
Open6.31
Bid6.45 x 1000
Ask6.49 x 1000
Day's Range6.31 - 6.71
52 Week Range6.02 - 27.32
Volume49,271
Avg. Volume55,528
Market Cap92.85M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-4.70
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
    GlobeNewswire

    Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation

    Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501 IRVINE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), received a No Objection Letter (NOL) from Health Canada for its

  • Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
    GlobeNewswire

    Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors

    IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the company’s Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development

  • Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
    GlobeNewswire

    Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

    IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13th at 2:00 pm EST. To regist